Covid-19 roundup: Re­gen­eron scores $2.6B US sup­ply deal for an­ti­body cock­tail; Brazil­ian re­searchers walk back ef­fi­ca­cy rate for Sino­vac's can­di­date

The US is con­tin­u­ing to buy up every dose of an­ti­body cock­tail that Re­gen­eron can pro­duce, sign­ing off on a $2.625 bil­lion deal to fol­low $450 mil­lion of in­vest­ments made in Ju­ly.

Whether Re­gen­eron can de­liv­er the best-case sce­nario — 1.25 mil­lion dos­es by the end of June — de­pends in large part on the FDA’s stance on the 1,200mg dose. The pair of an­ti­bod­ies, casiriv­imab and imde­vimab, is cur­rent­ly au­tho­rized on­ly at the 2,400mg dose lev­el (1,200mg each). Right now, the big biotech is in the process of de­liv­er­ing dos­es to treat 300,000 peo­ple fol­low­ing the emer­gency use au­tho­riza­tion in No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER